logo
Drugmaker reveals unsettling details of new strategy amid public outrage: 'It will be worse before it gets better'

Drugmaker reveals unsettling details of new strategy amid public outrage: 'It will be worse before it gets better'

Yahoo04-04-2025

A Danish drugmaker has revealed a stunning increase in pollution amid plans to boost production of its popular weight loss drug, and the matter will take some time to resolve.
As detailed by Reuters, Novo Nordisk announced in February that it saw a 23% increase in heat-trapping pollution last year, and it expects that percentage to climb as it churns out more of the weight management medication Wegovy to meet demand.
"Emissions come with growth," said Katrine DiBona, the drugmaker's corporate vice president of global public affairs and sustainability, adding: "It will be worse before it gets better. And that's also super-important for us to be very transparent on that."
In its 2024 annual report, Novo Nordisk reported it has made progress in reducing direct emissions and indirect emissions from purchased energy. However, 96% of its pollution comes from its supply chain.
The increase in Novo Nordisk's Scope 3 pollution highlights the need for solutions to better support sustainable growth, as pollution from dirty fuels is connected to millions of premature deaths every year. It also sparks a crucial discussion about how businesses build and market their products.
The drugmaker says in its report that it isn't backing down from its plan to achieve net zero by 2045, a concept in which its pollution generation is balanced by the amount absorbed.
In order to do that, it is eyeing a 33% reduction in Scope 3 pollution by 2033 compared to a 2024 baseline by switching to low-carbon materials and feedstock and supporting supplier transitions to clean energy.
However, Sasja Beslik, chief investment strategy officer at SDG Impact Japan, told Reuters that this interim goal didn't seem to be realistic given that the company hadn't decoupled its growth and emissions goals, raising questions of whether Novo Nordisk is giving lip service to sustainability to limit the risk of scrutiny or whether it is truly committed to its aims.
"Sounds like a fairy tale," Beslik said. "The sustainability angle is not part of the valuation of the stock and has no bearing on financial results, unfortunately."
While more than 1,800 of its suppliers have agreed to transition to renewable power, Novo Nordisk acknowledged in its report that "these measures will not be enough to meet our target," adding that it will also consider new and emerging technologies to "close the gap."
Do you worry about air pollution in and around your home?
Yes — always
Yes — often
Yes — sometimes
No — never
Click your choice to see results and speak your mind.
More broadly, Wegovy has been in the spotlight after an aggressive marketing campaign boosted its profile. Weight-loss drugs like Wegovy are also receiving hype on social media — no stranger to promoting the latest trends and fueling overconsumption.
As CBS News reported, health care professionals have raised concerns that some patients may not be using the medicines as intended amid the buzz, highlighting how mindful consumption can support both public health and the planet.
"My sense is that many people posting on social media are using these drugs but don't meet the medical criteria for using them," Dr. Cecilia Low Wang, a UCHealth expert in endocrinology, diabetes, and metabolism, said in a release.
"Even though this can be an amazing drug for many people, each person is unique and you need to make an informed decision," Low Wang added.
Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Football club investor Eagle files for US IPO, Bloomberg News reports
Football club investor Eagle files for US IPO, Bloomberg News reports

Yahoo

time30 minutes ago

  • Yahoo

Football club investor Eagle files for US IPO, Bloomberg News reports

(Reuters) -Eagle Football Holdings, one of the most active investors in global football clubs, has confidentially filed for a U.S. initial public offering, Bloomberg News reported on Friday. Reuters could not immediately confirm the report. The France-based company submitted a draft registration statement to the U.S. Securities and Exchange Commission, the report added, citing a company statement. The firm has been working with UBS Group AG on the potential IPO, the report said. Eagle Football, run by U.S. businessman John Textor, holds stakes in multiple football clubs including Olympique Lyonnais, Crystal Palace and Brazil's Botafogo. The SEC and Eagle Football did not immediately respond to request for comment outside regular business hours. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Traders pile into $80 US oil bets as tensions rise in Middle East
Traders pile into $80 US oil bets as tensions rise in Middle East

Yahoo

timean hour ago

  • Yahoo

Traders pile into $80 US oil bets as tensions rise in Middle East

(Reuters) -Traders on Friday exchanged the most $80 West Texas Intermediate (WTI) crude oil call options since January, expecting more upside to prices after Israeli airstrikes on Iran sparked fears of a wider Middle East conflict. Call options grant the holder a right to buy futures contract at the preset price and date, and a rise in volumes can help gauge market sentiment. About 33,411 contracts of August-2025 $80 call options for WTI crude oil were traded on Friday on a total trading volume of 681,000 contracts, marking the highest volume for these options this year, according to CME Group data. The last time trading was this high for $80 call contracts was on January 10, with 17,030 February-2025 $80 call options traded on a total trading volume of 301,866 contracts. Oil prices jumped on Friday and settled 7% higher as Israel and Iran launched air strikes, feeding investor worries that the combat could widely disrupt oil exports from the Middle East. U.S. West Texas Intermediate crude finished at $72.98 a barrel, up $4.94, or 7.62%. During the session, WTI jumped over 14% to its highest since January 21 at $77.62. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit

Yahoo

timean hour ago

  • Yahoo

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit

Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC's Advisory Committee on Immunization Practices on Wednesday, including several anti-vaccine proponents, after dismissing all 17 existing advisers. Kennedy justified the overhaul to 're-establish public confidence in vaccine science,' claiming, without providing specific evidence, that prior Biden-appointed members had conflicts of interest. The new eight-member committee represents the minimum allowed under ACIP's founding charter. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Martin Kulldorff, a biostatistician and epidemiologist, was among eight individuals selected by Kennedy to join the Advisory Committee on Immunization Practices (ACIP). Kulldorff has been an outspoken critic of COVID-19 lockdowns and vaccine mandates. His appointment has also raised questions due to his paid involvement in litigation against a major vaccine manufacturer, according to Reuters. Citing court records, Reuters notes that Kulldorff served as an expert witness in lawsuits against Merck & Co Inc (NYSE:MRK) over its Gardasil vaccine, which is used to prevent cancers caused by the human papillomavirus (HPV). The plaintiff accused the pharmaceutical company of not properly disclosing the vaccine's risks. Gardasil was approved in the U.S. in 2006 after going through clinical trials to prove its safety and a deposition in October, Kulldorff acknowledged that he had been paid $400 an hour for his work on the case and had billed approximately $33,000 through September. He also received a $4,000 retainer in connection with the North Carolina lawsuit, which was part of a broader legal effort encompassing about 200 related cases. In March, a federal judge ruled in favor of Merck in that particular case. Kulldorff's paid role as a litigation consultant could conflict with ACIP's established rules. According to the committee's guidelines, members are prohibited from serving as paid expert witnesses or litigation consultants in cases involving vaccine manufacturers while actively serving on the panel. Gardasil/Gardasil 9 sales declined 41% to $1.33 billion in the first quarter of 2025, primarily due to lower demand in China, partially offset by higher demand in most international regions, particularly in Japan, and higher pricing and demand in the U.S. Excluding China, sales grew 14%, or 16%, excluding the impact of foreign exchange. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom Photo: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit originally appeared on Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store